DK2585089T3 - Blokade af CCL18 signalering via CCR6 som en terapeutisk mulighed i fibrotiske sygdomme og cancer - Google Patents

Blokade af CCL18 signalering via CCR6 som en terapeutisk mulighed i fibrotiske sygdomme og cancer Download PDF

Info

Publication number
DK2585089T3
DK2585089T3 DK11727455.5T DK11727455T DK2585089T3 DK 2585089 T3 DK2585089 T3 DK 2585089T3 DK 11727455 T DK11727455 T DK 11727455T DK 2585089 T3 DK2585089 T3 DK 2585089T3
Authority
DK
Denmark
Prior art keywords
ccr6
ccl18
cancer
seq
nucleotides
Prior art date
Application number
DK11727455.5T
Other languages
English (en)
Inventor
Gernot Zissel
Joachim Müller-Quernheim
Antje Prasse
Original Assignee
Universitätsklinikum Freiburg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10167496.8A external-priority patent/EP2399598B1/en
Application filed by Universitätsklinikum Freiburg filed Critical Universitätsklinikum Freiburg
Application granted granted Critical
Publication of DK2585089T3 publication Critical patent/DK2585089T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/715—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons
    • G01N2333/7158—Assays involving receptors, cell surface antigens or cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)

Claims (5)

1. Farmaceutisk sammensætning omfattende en forbindelse der er i stand til at inhibere aktiviteten og/eller ekspression af CCL18 eller CCL20 til anvendelse i terapi, hvor forbindelsen der er i stand til at inhibere aktiviteten og/eller ekspression af CCL18 eller CCL20 er valgt fra gruppen bestående af (1) et isoleret opløseligt CCR6-receptorpolypeptid omfattende eller bestående af en aminosyresekvens valgt fra gruppen bestående af: (a) en aminosyresekvens der udviser mindst 80% identitet med sekvensen ifølge SEQ ID NO.: 1; og (b) et fragment af aminosyresekvensen ifølge (a); hvor det isolerede opløselige CCR6-receptorpolypeptid er i stand til at binde til CCL18 og/eller CCL20 og hvor det isolerede opløselige CCR6-receptorpolypeptid ikke omfatter et transmembrandomæne; (2) det isolerede opløselige CCR6-receptorpolypeptid ifølge (1), hvor aminosyresekvensen ifølge (a) omfatter mindst 8 fortløbende aminosyrer af sekvensen ifølge SEQ ID NO.:l.
2. Farmaceuticsk sammensætning til anvendelse ifølge krav 1, hvor sammensætningen omfatter en yderligere aktiv forbindelse der er egnet til behandling eller forebyggelse af en interstitiel lungesygdom og/eller cancer, hvor den yderligere aktive forbindelse der er egnet til behandling af en interstitiel lungesygdom er valgt fra gruppen bestående af et anti-inflammatorisk lægemiddel, en antioxidant, et anti-fibrotisk middel, minocyclin, sildenafil, thalidomid, et anti-TNF-antistof, etanercept, interferon gamma, et anti-IL-13-antistof, en endotelin inhibitor, Zileuton, et antikoagulerende middel, et makrolid, en phosphodiesterase 4 inhibitor, Aviptadil, en alpha-melanocyt-stimulerende og en hormontyrosinkinaseinhibitor og hvor den yderligere aktive forbindelse der er egnet til behandling af cancer er et kemoterapeutisk middel.
3. Farmaceutisk sammensætning til anvendelse ifølge krav 1 eller 2, hvor sammensætningen er til anvendelse til behandling eller forebyggelse af en interstitiel lungesygdom og/eller cancer.
4. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor den interstitielle lungesygdom er valgt fra gruppen bestående af idiopatisk lungefibrose, ikke-specifik interstitiel lungebetændelse, kryptogen organiserende lungebetændelse, respiratorisk bronkiolitis-associeret interstitiel lungesygdom, deskvamativ interstitiel lungebetændelse, akut interstitiel lungebetændelse og lymfocytisk interstitiel lungebetændelse.
5. Farmaceutisk sammensætning til anvendelse ifølge krav 3, hvor canceren er valgt fra gruppen bestående af adenocarcinom, fortrinsvis adenocarcinom i lungerne, pleuramesotheliom, kolorektal carcinom, prostatacarcinom, mammacarcinom, nyrecellecarcinom, hepatocellulær carcinom, Non-Hodgkin-lymfom og Hodgkin-lymfom.
DK11727455.5T 2010-06-28 2011-06-24 Blokade af CCL18 signalering via CCR6 som en terapeutisk mulighed i fibrotiske sygdomme og cancer DK2585089T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10167496.8A EP2399598B1 (en) 2010-06-28 2010-06-28 Blockade of CCL18 signaling via CCR6 as a therapeutic option in fibrotic diseases and cancer
EP11169326 2011-06-09
PCT/EP2011/060641 WO2012000906A1 (en) 2010-06-28 2011-06-24 Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

Publications (1)

Publication Number Publication Date
DK2585089T3 true DK2585089T3 (da) 2016-12-12

Family

ID=44313643

Family Applications (1)

Application Number Title Priority Date Filing Date
DK11727455.5T DK2585089T3 (da) 2010-06-28 2011-06-24 Blokade af CCL18 signalering via CCR6 som en terapeutisk mulighed i fibrotiske sygdomme og cancer

Country Status (8)

Country Link
US (3) US20130109629A1 (da)
EP (1) EP2585089B1 (da)
JP (2) JP5864564B2 (da)
CN (1) CN102958530B (da)
DK (1) DK2585089T3 (da)
ES (1) ES2604108T3 (da)
RU (1) RU2609649C2 (da)
WO (1) WO2012000906A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2585089B1 (en) * 2010-06-28 2016-10-12 Universitätsklinikum Freiburg Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
JP6932365B2 (ja) * 2015-05-14 2021-09-08 公立大学法人大阪 スキルス性胃癌の治療剤、及び胃癌の予後の予測方法
JP6895946B2 (ja) * 2015-07-14 2021-06-30 メディミューン，エルエルシー 癌の治療用組成物及び方法
CN108774629A (zh) * 2018-04-16 2018-11-09 中国科学院成都生物研究所 一种饰纹姬蛙肺泡上皮细胞的原代培养方法
CN112190708B (zh) * 2019-07-08 2023-09-05 上海交通大学医学院附属瑞金医院 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6713052B1 (en) * 1995-10-24 2004-03-30 Human Genome Sciences, Inc. Method of mobilizing stem cells with chemokine β-8
EP1422239A3 (en) 1995-10-24 2004-12-01 Smithkline Beecham Corporation Mobilization of hematopoietic stem cells using a chemokine
US7157418B1 (en) * 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US6998239B1 (en) * 1999-10-12 2006-02-14 Chemocentryx, Inc. Method for identifying a modulator of the binding of CCX CKR polypeptide to a chemokine
WO2001032874A2 (en) 1999-11-01 2001-05-10 Curagen Corporation Polypeptides and nucleic acids encoding same
AU2001250412A1 (en) * 2000-03-31 2001-10-08 Ipf Pharmaceuticals Gmbh Diagnostic and medicament for analysing the cell surface proteome of tumour and inflammatory cells and for treating tumorous and inflammatory diseases, preferably using specific chemokine receptor analysis and the chemokine receptor-ligand interaction
CA2421842A1 (en) * 2000-09-08 2002-03-14 Micromet Ag Antibody and/or chemokine constructs which bind to a chemokine receptor and their use in immunological disorders
AU2001296300A1 (en) * 2000-09-26 2002-04-08 Genaissance Pharmaceuticals, Inc. Haplotypes of the ccr6 gene
AU2003267088A1 (en) 2002-09-11 2004-04-30 Medical College Of Georgia Research Institute, Inc. Chemokine receptor antagonists as therapeutic agents
WO2004026893A2 (en) * 2002-09-23 2004-04-01 Rmf Dictagene S.A. Synthetic chemokines labeled at selected positions
JP2007501605A (ja) * 2003-08-08 2007-02-01 ジェノバ・リミテッド 心血管疾患に関連する分泌ポリペプチド種
WO2005095953A2 (en) * 2004-03-04 2005-10-13 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
CN100467487C (zh) * 2004-12-14 2009-03-11 北京大学 具有多种功能的多肽
JP2009096716A (ja) * 2006-01-19 2009-05-07 Eisai R & D Management Co Ltd 抗ｃｃｌ２０抗体による自己免疫疾患の治療
US20100143949A1 (en) * 2006-10-31 2010-06-10 George Mason Intellectual Properties, Inc. Biomarkers for colorectal cancer
EP2585089B1 (en) * 2010-06-28 2016-10-12 Universitätsklinikum Freiburg Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer

Also Published As

Publication number Publication date
JP5946937B2 (ja) 2016-07-06
JP2015180666A (ja) 2015-10-15
EP2585089B1 (en) 2016-10-12
RU2013103466A (ru) 2015-01-20
JP2013537405A (ja) 2013-10-03
EP2585089A1 (en) 2013-05-01
US10786550B2 (en) 2020-09-29
JP5864564B2 (ja) 2016-02-17
ES2604108T3 (es) 2017-03-03
US20130109629A1 (en) 2013-05-02
CN102958530A (zh) 2013-03-06
US20160354439A1 (en) 2016-12-08
WO2012000906A1 (en) 2012-01-05
RU2609649C2 (ru) 2017-02-02
CN102958530B (zh) 2017-11-14
US20210077577A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
US11203641B2 (en) Screening for anti-cancer compounds using netrin-1 activity
US20210077577A1 (en) Blockade of ccl18 signaling via ccr6 as a therapeutic option in fibrotic diseases and cancer
Zhang et al. Expression and functional characterization of ABCG2 in brain endothelial cells and vessels
US8158107B2 (en) Genes and proteins associated with angiogenesis and uses thereof
US9017682B2 (en) Treatment of neuroinflammatory conditions using antibodies directed against MCAM
EP2566965B1 (en) Antagonists of sema3e/plexind1 interaction as anti-cancer agents
US8377436B2 (en) Granulysin and uses thereof
CN110678757A (zh) 诊断或监测肾功能或诊断肾功能障碍的方法
EP2795337B1 (en) Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
EP2399598A1 (en) Blockade of CCL18 signaling via CCR6 as a therapeutic option in fibrotic diseases and cancer
Class et al. Patent application title: SCREENING METHODS TO IDENTIFY COMPOUNDS USEFUL IN THE PREVENTION AND/OR TREATMENT OF INFLAMMATORY CONDITIONS Inventors: Reginald Christophe Xavier Brys (Mechelen, BE) Reginald Christophe Xavier Brys (Mechelen, BE) Sonia Dupont (Romainville, FR) Assignees: GALAPAGOS NV